INT241798

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 5
Disease Relevance 2.07
Pain Relevance 0.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CHIT1) extracellular region (CHIT1) carbohydrate metabolic process (CHIT1)
lysosome (CHIT1)
Anatomy Link Frequency
liver 3
platelet 3
brain 2
leukocyte 1
spleen 1
CHIT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
peripheral neuropathy 13 80.84 Quite High
Pain 18 5.00 Very Low Very Low Very Low
Central nervous system 9 5.00 Very Low Very Low Very Low
imagery 8 5.00 Very Low Very Low Very Low
Inflammation 6 5.00 Very Low Very Low Very Low
cytokine 2 5.00 Very Low Very Low Very Low
Analgesic 2 5.00 Very Low Very Low Very Low
Paresthesia 2 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
palliative 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Gauchers Disease 190 98.52 Very High Very High Very High
Splenomegaly 8 97.52 Very High Very High Very High
Hepatomegaly 6 95.92 Very High Very High Very High
Neurologic Manifestations 10 94.84 High High
Weight Loss 16 94.40 High High
Diarrhoea 18 93.76 High High
Peripheral Neuropathy 13 80.84 Quite High
Tremor 9 79.80 Quite High
Proteostasis Deficiencies 1 69.52 Quite High
Disease 39 31.68 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels).
Negative_regulation (decreased) of Gene_expression (levels) of chitotriosidase in platelet
1) Confidence 0.15 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.28 Pain Relevance 0
After a total of 12 monthsÂ’ treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1).
Negative_regulation (decreased) of Gene_expression (levels) of chitotriosidase in liver
2) Confidence 0.10 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.38 Pain Relevance 0.03
Unlike recombinant enzymes, SRT agents are small molecules that can cross the blood-brain barrier.59 Although improved pulmonary function, and a significant decrease in chitotriosidase levels have been observed in patients with GD type 3, miglustat unfortunately, does not appear to have any significant benefits on the neurological manifestations of GD.60
Negative_regulation (decrease) of Gene_expression (levels) of chitotriosidase in brain associated with gauchers disease and neurologic manifestations
3) Confidence 0.06 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2909498 Disease Relevance 0.75 Pain Relevance 0.04
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels).
Negative_regulation (decreased) of in leukocyte Gene_expression (levels) of chitotriosidase in platelet
4) Confidence 0.05 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945057 Disease Relevance 0.28 Pain Relevance 0
After a total of 12 monthsÂ’ treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1).
Negative_regulation (decreased) of in spleen Gene_expression (levels) of chitotriosidase in liver
5) Confidence 0.03 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504062 Disease Relevance 0.38 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox